Scinopharm provides one-stop CMC (Chemistry, Manufacturing, and Controls) solutions from high potency APIs to injectable drug formulations and its market authorization application. Our dedicated team offers high integrity support on CMC technical guidance and regulatory support from preclinical CMC strategies to regulatory filings and post launch process improvement efforts. Accelerating your drug development process and ensuring knowledge retention throughout the entire drug lifecycle. Scinopharm has completed over 200 CDMO projects, over 70 generic drug developments, 69 US DMFs, and over 950 DMFs registered in over 100 countries, serving over 300 pharmaceutical companies worldwide. ScinoPharm commits no competition with customers in their end markets and delivers flexible, reliable, and cost-effective high-value solutions.

Since its foundation, ScinoPharm Taiwan has placed patient safety and drug efficacy as its top priorities, while embedding safety, hygiene, and environmental protection into its core values of sustainable development. These principles shape our corporate culture and guide daily operations and decision-making. We are committed to providing high-quality APIs and finished drug products that meet international standards, ensuring process safety, environmental sustainability, and employee well-being. As our business has expanded from APIs to drug product manufacturing, SPT has strengthened its quality systems by integrating advanced technologies and risk-based management, ensuring each batch delivers its intended therapeutic effect with the highest level of patient protection. SPT has successfully passed inspections by global regulatory authorities—including TFDA, FDA, EMA, PMDA and ANVISA. This track record demonstrates worldwide confidence in our quality. Through collaboration with leading pharmaceutical partners, we have built a robust quality management framework aligned with ICH, PIC/S, FDA, and EMA guidelines, securing compliance and competitiveness across global markets.